Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.89 USD | +4.61% | -6.37% | -49.44% |
04-15 | RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating | MT |
04-11 | Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-49.44% | 382M | |
-4.38% | 184B | |
-2.26% | 107B | |
-4.04% | 67.52B | |
+1.14% | 50.06B | |
+9.92% | 45.67B | |
+3.40% | 41B | |
+3.20% | 26.73B | |
+3.82% | 26.47B | |
+15.23% | 25.05B |
- Stock Market
- Equities
- NVRO Stock
- News Nevro Corp.
- Nevro : Gets FDA Approval For Chronic Pain Treatment; Expects Q2 Revenue of $102.3 Million